97 related articles for article (PubMed ID: 21522056)
1. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Hansard MJ; Jackson MJ; Smith LA; Rose S; Jenner P
Behav Pharmacol; 2011 Jun; 22(3):269-74. PubMed ID: 21522056
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
Damaj MI; Carroll FI; Eaton JB; Navarro HA; Blough BE; Mirza S; Lukas RJ; Martin BR
Mol Pharmacol; 2004 Sep; 66(3):675-82. PubMed ID: 15322260
[TBL] [Abstract][Full Text] [Related]
3. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
4. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
5. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
[TBL] [Abstract][Full Text] [Related]
6. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
[TBL] [Abstract][Full Text] [Related]
7. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective analysis of hydroxybupropion and application to drug interaction studies.
Xu H; Loboz KK; Gross AS; McLachlan AJ
Chirality; 2007 Mar; 19(3):163-70. PubMed ID: 17167747
[TBL] [Abstract][Full Text] [Related]
10. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
11. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Iravani MM; Costa S; Al-Bargouthy G; Jackson MJ; Zeng BY; Kuoppamäki M; Obeso JA; Jenner P
Eur J Neurosci; 2005 Sep; 22(6):1305-18. PubMed ID: 16190886
[TBL] [Abstract][Full Text] [Related]
12. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Smith L; De Salvia M; Jenner P; Marsden CD
Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
[TBL] [Abstract][Full Text] [Related]
13. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
[TBL] [Abstract][Full Text] [Related]
14. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
[TBL] [Abstract][Full Text] [Related]
16. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
17. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
Mihara T; Iwashita A; Matsuoka N
Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Jackson MJ; Al-Barghouthy G; Pearce RK; Smith L; Hagan JJ; Jenner P
Pharmacol Biochem Behav; 2004 Nov; 79(3):391-400. PubMed ID: 15582011
[TBL] [Abstract][Full Text] [Related]
19. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
20. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
